824 filings
Page 4 of 42
8-K
fulfct0h8i
19 Apr 23
Entry into a Material Definitive Agreement
5:25pm
CORRESP
zh7n03 yo
19 Apr 23
Correspondence with SEC
12:00am
8-K
w87 zduuv
14 Apr 23
Other Events
8:33am
8-K
2lnsso3gbnogw
10 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am
UPLOAD
qvd8vfo3j9hl
7 Apr 23
Letter from SEC
12:00am
8-K
pnswh 4la1ss7yv78bo
24 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
bhjbhorvyt
14 Feb 23
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
7:46am
8-K
0xhyq4 f5
9 Feb 23
Soligenix Announces Reverse Stock Split
7:45am
DEFA14A
zbnt10hz 9l
11 Jan 23
Additional proxy soliciting materials
8:02am
8-K
3a70gi423gy plhzhrju
11 Jan 23
Other Events
8:00am
8-K
ptya0puwzhk8t69iy5w2
27 Dec 22
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
4:25pm
8-A12G
9i74nc9fx9kt
27 Dec 22
Registration of securities
4:05pm
8-K
97mpbcu11b 62ycb13iq
23 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
pdq2oa2f 8k
19 Dec 22
Other Events
8:00am
8-K
m640ooj yi
15 Dec 22
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
8:14am
8-K
meh3p hpp
18 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:45pm